Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs? (Q35093571)

6 August 2017

1 reference

title

Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs? (English)

1 reference

6 August 2017

anti-retroviral agent

0 references

author name string

Rob E Aarnoutse

1

1 reference

6 August 2017

Jonathan M Schapiro

2

1 reference

6 August 2017

Charles A B Boucher

3

1 reference

6 August 2017

Yechiel A Hekster

4

1 reference

6 August 2017

David M Burger

5

1 reference

6 August 2017

1 January 2003

1 reference

6 August 2017

1 reference

6 August 2017

63

1 reference

6 August 2017

8

1 reference

6 August 2017

741-753

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200363080-00002

6 August 2017

0 references

cites work

Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons

1 reference

12 December 2020

Nephropathy and renal colic in patients treated with indinavir, ritonavir plus indinavir or ritonavir plus saquinavir

1 reference

12 December 2020

Diurnal variation of plasma protease inhibitor concentrations

1 reference

12 December 2020

Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers

1 reference

12 December 2020

Pharmacokinetic parameters of protease inhibitors and the Cmin/IC50 ratio: call for consensus

1 reference

12 December 2020

Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors

1 reference

12 December 2020

Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

1 reference

12 December 2020

Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients

1 reference

12 December 2020

Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir

1 reference

12 December 2020

Early virological failure in naive human immunodeficiency virus patients receiving saquinavir (soft gel capsule)-stavudine-zalcitabine (MIKADO trial) is not associated with mutations conferring viral resistance

1 reference

12 December 2020

Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.

1 reference

12 December 2020

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

1 reference

12 December 2020

PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results.

1 reference

12 December 2020

Limited sampling strategies for the estimation of the systemic exposure to the HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapine

1 reference

12 December 2020

Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy

1 reference

12 December 2020

Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations

1 reference

12 December 2020

Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: theory and practice

1 reference

12 December 2020

ABC of monitoring drug therapy. Making the most of plasma drug concentration measurements

1 reference

12 December 2020

The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

1 reference

12 December 2020

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing

1 reference

12 December 2020

Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study

1 reference

12 December 2020

High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease

1 reference

12 December 2020

Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection

1 reference

12 December 2020

Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients

1 reference

12 December 2020

Best practice in therapeutic drug monitoring

1 reference

12 December 2020

Pharmacokinetic variability and strategy for therapeutic drug monitoring of saquinavir (SQV) in HIV-1 infected individuals

1 reference

12 December 2020

Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients

1 reference

12 December 2020

Individualizing salvage regimens: the inhibitory quotient (Ctrough/IC50) as predictor of virological response.

1 reference

12 December 2020

The inhibitory quotient. A method for interpreting minimum inhibitory concentration data

1 reference

12 December 2020

A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir).

1 reference

12 December 2020

Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients

1 reference

12 December 2020

An argument for routine therapeutic drug monitoring of HIV-1 protease inhibitors during pregnancy

1 reference

12 December 2020

Addressing the challenges of adherence

1 reference

12 December 2020

Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia

1 reference

12 December 2020

Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease

1 reference

12 December 2020

The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy.

1 reference

12 December 2020

Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).

1 reference

12 December 2020

Interactions among drugs for HIV and opportunistic infections

1 reference

12 December 2020

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

12 December 2020

HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy

1 reference

12 December 2020

The utility of inhibitory quotients in determining the relative potency of protease inhibitors

1 reference

12 December 2020

Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir

1 reference

12 December 2020

Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy

1 reference

12 December 2020

High concentrations of nelfinavir as an independent risk factor for lipodystrophy in human immunodeficiency virus-infected patients

1 reference

12 December 2020

Concentration-controlled zidovudine therapy

1 reference

12 December 2020

Concentration-controlled compared with conventional antiretroviral therapy for HIV infection

1 reference

12 December 2020

High-performance liquid chromatography of HIV protease inhibitors in human biological matrices

1 reference

12 December 2020

Reliability of Cmin: inhibitory concentration ratios

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients

1 reference

12 December 2020

Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir

1 reference

12 December 2020

Variability in trough plasma saquinavir concentrations in HIV patients--a case for therapeutic drug monitoring

1 reference

12 December 2020

Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability.

1 reference

12 December 2020

The human drug metabolizing cytochromes P450.

1 reference

12 December 2020

Indinavir plasma protein binding in HIV-1-infected adults

1 reference

12 December 2020

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

1 reference

12 December 2020

Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring

1 reference

12 December 2020

Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study

1 reference

12 December 2020

Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors

1 reference

12 December 2020

The role of therapeutic drug monitoring in treatment of HIV infection

1 reference

12 December 2020

Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children

1 reference

12 December 2020

International interlaboratory quality control program for measurement of antiretroviral drugs in plasma

1 reference

12 December 2020

High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen

1 reference

12 December 2020

Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo

1 reference

12 December 2020

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study

1 reference

12 December 2020

Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: relationship to virologic response

1 reference

12 December 2020

Patient-reported nonadherence to HAART is related to protease inhibitor levels

1 reference

12 December 2020

Standard methods to measure HIV drug concentrations

1 reference

12 December 2020

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

1 reference

12 December 2020

Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy

1 reference

12 December 2020

A comparison study of multiple measures of adherence to HIV protease inhibitors.

1 reference

12 December 2020

A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy

1 reference

12 December 2020

Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens

1 reference

12 December 2020

Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients

1 reference

12 December 2020

Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons

1 reference

12 December 2020

High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals

1 reference

12 December 2020

Methods for integration of pharmacokinetic and phenotypic information in the treatment of infection with human immunodeficiency virus

1 reference

12 December 2020

Efficacy of highly active antiretroviral therapy in HIV-1 infected children

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection

1 reference

12 December 2020

Liver toxicity caused by nevirapine

1 reference

12 December 2020

Relationship between efficacy, tolerance, and plasma drug concentration of ritonavir in children with advanced HIV infection.

1 reference

12 December 2020

Higher efavirenz plasma levels correlate with development of insomnia

1 reference

12 December 2020

Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients

1 reference

12 December 2020

Practical implications for the interpretation of minimum plasma concentration/inhibitory concentration ratios

1 reference

12 December 2020

Therapeutic drug monitoring of HIV-protease inhibitors to assess noncompliance

1 reference

12 December 2020

Indinavir concentrations and antiviral effect

1 reference

12 December 2020

Public Health Implications of Antiretroviral Therapy and HIV Drug Resistance

1 reference

12 December 2020

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

1 reference

12 December 2020

CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid

1 reference

12 December 2020

Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities

1 reference

12 December 2020

The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring

1 reference

12 December 2020

Pharmacokinetics and resistance mutations affect virologic response to ritonavir/saquinavir-containing regimens

1 reference

12 December 2020

Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience

1 reference

12 December 2020

Pharmacogenetics: the therapeutic drug monitoring of the future?

1 reference

12 December 2020

Pharmacologic considerations for therapeutic success with antiretroviral agents

1 reference

12 December 2020

Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy.

1 reference

12 December 2020

Predictors of optimal virological response to potent antiretroviral therapy

1 reference

12 December 2020

Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine.

1 reference

12 December 2020

Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients

1 reference

12 December 2020

Low-dose ritonavir moderately enhances nelfinavir exposure

1 reference

12 December 2020

Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies.

1 reference

12 December 2020

Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients.

1 reference

12 December 2020

Therapeutic drug monitoring

1 reference

12 December 2020

Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes?

1 reference

12 December 2020

10.2165/00003495-200363080-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

6 August 2017

0 references

1 reference